Federal Register / Vol. 89, No. 179 / Monday, September 16, 2024 / Notices 75549 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; Ex Vivo 

Models for Studies at the Intersection of HIV 

and Poly-Substance Use. 

Date: October 22, 2024. 

Time: 12:00 p.m. to 2:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Ipolia R. Ramadan, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

National Institute on Drug Abuse, NIH, 301 

North Stonestreet Avenue, MSC 6021, 

Bethesda, MD 20892, (301) 827–4471, 

ramadanir@mail.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Exploratory Studies to Investigate 

Mechanisms of HIV Infection, Replication, 

Latency, and/or Pathogenesis in the Context 

of Substance Use Disorders. 

Date: November 7, 2024. 

Time: 11:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Soyoun Cho, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

National Institute on Drug Abuse, NIH, 301 

North Stonestreet Avenue, MSC 6021, 

Bethesda, MD 20892, (301) 594–9460, 

Soyoun.cho@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: September 10, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–20917 Filed 9–13–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel, Multi-Scale 

analysis of ADRD. 

Date: October 21–22, 2024. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute on Aging, 5601 

Fishers Ln, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Nijaguna Prasad, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, National Institute on Aging, 5601 

Fishers Lane, Rm 2W200, Rockville, MD 

20852, (301) 496–9667, prasadnb@

nia.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: September 10, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–20955 Filed 9–13–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Interagency Coordinating Committee 

on the Validation of Alternative 

Methods Biennial Progress Report: 

2022–2023; Availability of Report 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Toxicology 

Program (NTP) Interagency Center for 

the Evaluation of Alternative 

Toxicological Methods (NICEATM) 

announces availability of the 

Interagency Coordinating Committee on 

the Validation of Alternative Methods 

(ICCVAM) Biennial Progress Report: 

2022–2023. 

ADDRESSES: The report is available at 

https://ntp.niehs.nih.gov/go/ 

2023iccvamreport. 

FOR FURTHER INFORMATION CONTACT: Dr. 

Nicole Kleinstreuer, Director, National 

Toxicology Program (NTP) Interagency 

Center for the Evaluation of Alternative 

Toxicological Methods (NICEATM), 

email: nicole.kleinstreuer@nih.gov, 

telephone: 984–287–3150. 

SUPPLEMENTARY INFORMATION: 

Background: The ICCVAM 

Authorization Act of 2000 established 

ICCVAM as a permanent interagency 

committee of the National Institute of 

Environmental Health Sciences (NIEHS) 

under NICEATM. ICCVAM’s mission is 

to facilitate development, validation, 

and regulatory acceptance of new and 

revised regulatory test methods that 

reduce, refine, or replace the use of 

animals in testing while maintaining 

and promoting scientific quality and the 

protection of human health, animal 

health, and the environment. 

A provision of the ICCVAM 

Authorization Act states that ICCVAM 

shall prepare ‘‘reports to be made 

available to the public on its progress 

under this Act.’’ The twelfth progress 

report describing ICCVAM activities and 

accomplishments from January 2022 

through December 2023 is now 

available. 

Summary of Report Contents: Key 

ICCVAM, ICCVAM agency, and 

NICEATM accomplishments 

summarized in the report include: 

• Development of an updated 

document on ‘‘Validation, Qualification, 

and Regulatory Acceptance of New 

Approach Methodologies,’’ by the 

ICCVAM Validation Workgroup. This 

document describes an approach to 

validation of new approach 

methodologies (NAMs) that reflects 

modern toxicity testing, placing less 

emphasis on replacement of in vivo 

tests with a single alternative method 

and more emphasis on integrating 

results from multiple in vitro and in 

chemico assays and in silico 

approaches. 

• Publication of articles describing 

U.S. and international information 

needs and testing requirements for 

nanomaterials, ecotoxicity, and acute 

systemic toxicity. An ICCVAM 

workgroup also published an awardwinning article describing federal 

agency application of in vitro to in vivo 

extrapolation. 

• Curation and publication of a 

human skin sensitization database. 


lotter on DSK11XQN23PROD with NOTICES1